HIV Envelope Protein gp41
"HIV Envelope Protein gp41" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING.
| Descriptor ID |
D015700
|
| MeSH Number(s) |
D12.776.543.512.500.330 D12.776.964.775.325.164.200 D12.776.964.775.562.500.200 D12.776.964.970.880.325.164.200 D12.776.964.970.880.910.330 D23.050.327.520.330
|
| Concept/Terms |
HIV Envelope Protein gp41- HIV Envelope Protein gp41
- Envelope Protein gp41, HIV
- HTLV-III gp41
- gp41(HIV)
- HIV Transmembrane Protein gp41
- env Protein gp41, HIV
- gp41 Envelope Protein, HIV
|
Below are MeSH descriptors whose meaning is more general than "HIV Envelope Protein gp41".
Below are MeSH descriptors whose meaning is more specific than "HIV Envelope Protein gp41".
This graph shows the total number of publications written about "HIV Envelope Protein gp41" by people in this website by year, and whether "HIV Envelope Protein gp41" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 1 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 3 | 0 | 3 |
| 2011 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "HIV Envelope Protein gp41" by people in Profiles.
-
Differences in serum IgA responses to HIV-1 gp41 in elite controllers compared to viral suppressors on highly active antiretroviral therapy. PLoS One. 2017; 12(7):e0180245.
-
Bovine papillomavirus-like particles presenting conserved epitopes from membrane-proximal external region of HIV-1 gp41 induced mucosal and systemic antibodies. Vaccine. 2013 Nov 04; 31(46):5422-9.
-
Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency. Biophys J. 2011 Apr 20; 100(8):1960-8.
-
Ternary complex formation of human immunodeficiency virus type 1 Env, CD4, and chemokine receptor captured as an intermediate of membrane fusion. J Virol. 2005 Sep; 79(17):11161-9.
-
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005 Aug 13-19; 366(9485):549-55.
-
The cytoplasmic tail slows the folding of human immunodeficiency virus type 1 Env from a late prebundle configuration into the six-helix bundle. J Virol. 2005 Jan; 79(1):106-15.
-
Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. J Virol. 2004 Aug; 78(15):8342-8.
-
Enriching for HIV-infected cells using anti-gp41 antibodies indirectly conjugated to magnetic microbeads. Biotechniques. 2004 Jan; 36(1):139-47.
-
Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion. J Virol. 2003 May; 77(10):5829-36.
-
HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell. 2003 Mar; 14(3):926-38.